Ken Griffin Verona Pharma PLC Transaction History
Citadel Advisors LLC
- $505 Billion
- Q3 2024
A detailed history of Ken Griffin (Citadel Advisors LLC) transactions in Verona Pharma PLC stock. As of the latest transaction made, Citadel Advisors LLC holds 16,100 shares of VRNA stock, worth $624,841. This represents 0.0% of its overall portfolio holdings.
Number of Shares
16,100
Previous 140,100
88.51%
Holding current value
$624,841
Previous $2.03 Million
77.14%
% of portfolio
0.0%
Previous 0.0%
Shares
13 transactions
Others Institutions Holding VRNA
# of Institutions
166Shares Held
68.7MCall Options Held
704KPut Options Held
685K-
Perceptive Advisors LLC New York, NY6.32MShares$245 Million4.75% of portfolio
-
Nea Management Company, LLC Timonium, MD5.58MShares$217 Million12.27% of portfolio
-
Ra Capital Management, L.P. Boston, MA5.01MShares$194 Million2.01% of portfolio
-
Lee Ainslie Maverick Capital LTD | Dallas, Tx4.22MShares$164 Million2.52% of portfolio
-
Vivo Capital, LLC Palo Alto, CA3.55MShares$138 Million14.95% of portfolio
About Verona Pharma plc
- Ticker VRNA
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 60,954,200
- Market Cap $2.37B
- Description
- Verona Pharma plc, a clinical stage biopharmaceutical company, focuses on development and commercialization of therapies for the treatment of respiratory diseases with unmet medical needs. The company's product candidate is ensifentrine, an inhaled and dual inhibitor of the phosphodiesterase (PDE) 3 and PDE4 enzymes that acts as both a bronchodi...